Physiologically based pharmacokinetic modelling and in vivo [I]/K i accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate

British Journal of Pharmacology

Volumn 171, Issue 4, 2014, Pages 1043-1053

  Zhao, Yuansheng ^a   Hu, Zhe Yi ^b  

^a HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

'in vivo' Ki; dabigatran etexilate; digoxin; P glycoprotein; physiologically based pharmacokinetic modelling

Indexed keywords

AMIODARONE; CLARITHROMYCIN; DABIGATRAN ETEXILATE; DIGOXIN; DRONEDARONE; QUINIDINE; RIFAMPICIN; VERAPAMIL;

AREA UNDER THE CURVE; ARTICLE; BIOLOGICAL MODEL; CELL MEMBRANE PERMEABILITY; DRUG BLOOD LEVEL; DRUG TRANSPORT; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL TRANSIT; HUMAN; IN VIVO STUDY; INTESTINE MUCOSA PERMEABILITY; LIPOPHILICITY; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; PHARMACOKINETICS; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; PLASMA CONCENTRATION-TIME CURVE; PREDICTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; VALIDATION PROCESS;

'IN VIVO' KI; DABIGATRAN ETEXILATE; DIGOXIN; P-GLYCOPROTEIN; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELLING;

AMIODARONE; BENZIMIDAZOLES; BETA-ALANINE; CLARITHROMYCIN; DIGOXIN; DRUG INTERACTIONS; HUMANS; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; PYRIDINES; QUINIDINE; VERAPAMIL;

EID: 84893094436     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12533     Document Type: Article

References (48)

1. Becquemont L, Verstuyft C, Kerb R, Brinkmann U, Lebot M, Jaillon P, et al. (2001). Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther 70: 311-316.
2. Bentz J, O'Connor MP, Bednarczyk D, Coleman J, Lee C, Palm J, et al. (2013). Variability in P-glycoprotein inhibitory potency (IC50) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria. Drug Metab Dispos 41: 1347-1366.
3. Bischoff KB, Dedrick RL, Zaharko DS, Longstreth JA, (1971). Methotrexate pharmacokinetics. J Pharm Sci 60: 1128-1133.
4. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W, (2008). The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 36: 386-399.
5. Bradshaw-Pierce EL, Eckhardt SG, Gustafson DL, (2007). A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Clin Cancer Res 13: 2768-2776.
6. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361: 1139-1151.
7. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB, (1999). OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27: 866-871.
8. Delavenne X, Ollier E, Basset T, Bertoletti L, Accassat S, Garcin A, et al. (2013). A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. Br J Clin Pharmacol 76: 107-113.
9. Ding R, Tayrouz Y, Riedel KD, Burhenne J, Weiss J, Mikus G, et al. (2004). Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther 76: 73-84.
10. Draft Guidance/Guidance for Industry (2012). Drug interaction studies-study Design, data analysis, implications for dosing, and labeling recommendations. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf (11/18/2013).
11. Eckermann G, Lahu G, Nassr N, Bethke TD, (2012). Absence of pharmacokinetic interaction between roflumilast and digoxin in healthy adults. J Clin Pharmacol 52: 251-257.
12. Ellens H, Deng S, Coleman J, Bentz J, Taub ME, Ragueneau-Majlessi I, et al. (2013). Application of receiver operating characteristic analysis to refine the prediction of potential digoxin drug interactions. Drug Metab Dispos 41: 1367-1374.
13. Fenner KS, Troutman MD, Kempshall S, Cook JA, Ware JA, Smith DA, et al. (2009). Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther 85: 173-181.
14. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, et al. (1999). The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104: 147-153.
15. Härtter S, Koenen-Bergmann M, Sharma A, Nehmiz G, Lemke U, Timmer W, et al. (2012). Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol 74: 490-500.
16. Härtter S, Sennewald R, Nehmiz G, Reilly P, (2013). Oral bioavailability of dabigatran etexilate (Pradaxa(®)) after co-medication with verapamil in healthy subjects. Br J Clin Pharmacol 75: 1053-1062.
17. van Heeswijk RP, Bourbeau M, Campbell P, Seguin I, Chauhan BM, Foster BC, et al. (2006). Time-dependent interaction between lopinavir/ritonavir and fexofenadine. J Clin Pharmacol 46: 758-767.
18. Hsu V, de L T Vieira M, Zhao P, Zhang L, Zheng JH, Nordmark A, et al. (2013). Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations. Clin Pharmacokinet. doi: 10.1007/s40262-013-0117-y. (in press)
19. Hu ZY, (2013). Disposition pathway-dependent approach for predicting organic anion-transporting polypeptide-mediated drug-drug interactions. Clin Pharmacokinet 52: 433-441.
20. Hu ZY, Parker RB, Laizure SC, (2012). In vivo information-guided prediction approach for assessing the risks of drug-drug interactions associated with circulating inhibitory metabolites. Drug Metab Dispos 40: 1487-1494.
21. Hu ZY, Parker RB, Herring VL, Laizure SC, (2013). Conventional liquid chromatography/triple quadrupole mass spectrometry based metabolite identification and semi-quantitative estimation approach in the investigation of in vitro dabigatran etexilate metabolism. Anal Bioanal Chem 405: 1695-1704.
22. Kramer WG, Kolibash AJ, Lewis RP, Bathala MS, Visconti JA, Reuning RH, (1979). Pharmacokinetics of digoxin: relationship between response intensity and predicted compartmental drug levels in man. J Pharmacokinet Biopharm 7: 47-61.
23. Laizure SC, Parker RB, Herring VL, Hu ZY, (2013). Identification of carboxylesterase-dependent dabigatran etexilate hydrolysis. Drug Metab Dispos. doi: 10.1124/dmd.113.054353. (in press)
24. Meyer M, Schneckener S, Ludewig B, Kuepfer L, Lippert J, (2012). Using expression data for quantification of active processes in physiologically based pharmacokinetic modeling. Drug Metab Dispos 40: 892-901.
25. Neuhoff S, Yeo KR, Barter Z, Jamei M, Turner DB, Rostami-Hodjegan A, (2013a). Application of permeability-limited physiologically-based pharmacokinetic models: Part I-digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux. J Pharm Sci 102: 3145-3160.
26. Neuhoff S, Yeo KR, Barter Z, Jamei M, Turner DB, Rostami-Hodjegan A, (2013b). Application of permeability-limited physiologically-based pharmacokinetic models: Part II-prediction of p-glycoprotein mediated drug-drug interactions with digoxin. J Pharm Sci 102: 3161-3173.
27. Oosterhuis B, Jonkman JH, Andersson T, Zuiderwijk PB, Jedema JN, (1991). Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmacol 32: 569-572.
28. Ragueneau I, Poirier JM, Radembino N, Sao AB, Funck-Brentano C, Jaillon P, (1999). Pharmacokinetic and pharmacodynamic drug interactions between digoxin and macrogol 4000, a laxative polymer, in healthy volunteers. Br J Clin Pharmacol 48: 453-456.
29. Rodgers T, Rowland M, (2006). Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 95: 1238-1257.
30. Rodgers T, Rowland M, (2007). Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res 24: 918-933.
31. Rodgers T, Leahy D, Rowland M, (2005). Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 94: 1259-1276.
32. Rodin SM, Johnson BF, Wilson J, Ritchie P, Johnson J, (1988). Comparative effects of verapamil and isradipine on steady-state digoxin kinetics. Clin Pharmacol Ther 43: 668-672.
33. Rowland M, Matin SB, (1973). Kinetics of drug-drug interactions. J Pharmacokinet Biopharm 1: 553-567.
34. Shimizu M, Uno T, Sugawara K, Tateishi T, (2006). Effects of single and multiple doses of itraconazole on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Br J Clin Pharmacol 62: 372-376.
35. Southworth MR, Reichman ME, Unger EF, (2013). Dabigatran and postmarketing reports of bleeding. N Engl J Med 368: 1272-1274.
36. Stangier J, (2008). Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 47: 285-295.
37. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W, (2007). The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64: 292-303.
38. Stangier J, Stähle H, Rathgen K, Roth W, Shakeri-Nejad K, (2008). Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol 48: 1411-1419.
39. Stangier J, Stähle H, Rathgen K, Roth W, Reseski K, Körnicke T, (2012). Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, with coadministration of digoxin. J Clin Pharmacol 52: 243-250.
40. Tateishi T, Miura M, Suzuki T, Uno T, (2008). The different effects of itraconazole on the pharmacokinetics of fexofenadine enantiomers. Br J Clin Pharmacol 65: 693-700.
41. Thelen K, Coboeken K, Willmann S, Burghaus R, Dressman JB, Lippert J, (2011). Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: oral solutions. J Pharm Sci 100: 5324-5345.
42. Thelen K, Coboeken K, Willmann S, Dressman JB, Lippert J, (2012). Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part II: extension to describe performance of solid dosage forms. J Pharm Sci 101: 1267-1280.
43. Vaidyanathan S, Camenisch G, Schuetz H, Reynolds C, Yeh CM, Bizot MN, et al. (2008). Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol 48: 1323-1338.
44. Verstuyft C, Strabach S, El-Morabet H, Kerb R, Brinkmann U, Dubert L, et al. (2003). Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. Clin Pharmacol Ther 73: 51-60.
45. Weiss M, (2007). Mechanistic modeling of digoxin distribution kinetics incorporating slow tissue binding. Eur J Pharm Sci 30: 256-263.
46. Westphal K, Weinbrenner A, Giessmann T, Stuhr M, Franke G, Zschiesche M, et al. (2000). Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther 68: 6-12.
47. Yasui-Furukori N, Uno T, Sugawara K, Tateishi T, (2005). Different effects of three transporting inhibitors, verapamil, cimetidine, and probenecid, on fexofenadine pharmacokinetics. Clin Pharmacol Ther 77: 17-23.
48. Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ, et al. (2011). Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther 89: 259-267.